References
- Aguilera-Castro, L., Ferre-Aracil, C., Garcia-Garcia-de-Paredes, A., Rodriguez-de-Santiago, E., Lopez-Sanroman, A. (2017). Management of complex perianal Crohn’s disease. Ann. Gastroenterol., 230 (1), 33–44.
- Ankrum, J., Ong, J., Karp, J. (2014). Mesenchymal stem cells: Immune evasive, not immune privileged. Nat. Biotech., 32, 252–260.10.1038/nbt.2816432064724561556
- Augello, A., Tasso, R., Negrini, S., Amateis, A., Indiveri, F., Cancedda, R., Pennesi, G. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol., 35, 1482–1490.10.1002/eji.20042540515827960
- Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., Mcintosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A., Hoffman, R. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol., 30, 42–48.
- Ciccocioppo, R., Bernardo, M. E., Sgarella, A., Maccario, R., Avanzini, M. A., Ubezio, C., Minelli, A., Alvisi, C., Vanoli, A., Calliada, F., Dionigi, P., Perotti, C., Locatelli, F., Corazzaa, G. R. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut, 60 (6), 788–798.10.1136/gut.2010.21484121257987
- Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonell, F., Parc, R., Gendre, J. P. (2002). Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis., 8, 244–250.10.1097/00054725-200207000-0000212131607
- Dignass, A., Van Assche, G., Lindsay, J. O., Lemann, M., Soderholm, J., Colombel, J. F., Danese, S., D’Hoore, A., Gassull, M., Gomollon, F. et al. (2010). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. J. Crohn’s Colitis, 4, 28–62.10.1016/j.crohns.2009.12.00221122489
- Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P., Matteucci, P., Grisanti, S., Gianni, A. M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838–3843.10.1182/blood.V99.10.383811986244
- Duijvestein, M., Wildenberg, M. E., Welling, M. M., Hennink, S., Molendijk, I., van Zuylen, V. L., Bosse, T., Vos, A. C. W., de Jonge-Muller, E. S. M., Roelofs, H. et al. (2011). Pretreatment with interferon- γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells., 29,1549–1558.10.1002/stem.69821898680
- De la Portilla, F., García-Cabrera, A. M., Rodríguez- Jiménez, R. M., Reyes, M. L., García-Olmo, D. (2016). Autologous and Allogeneic Stem Cell Transplantation for Treatment of Crohn’s Fistulae/New Insights into Inflammatory Bowel Disease. 262 pp. https://www.intechopen.com/books/new-insights-into-inflammatory-bowel-disease/autologous-and-allogeneic-stem-cell-transplantationfor-treatment-of-crohn-s-fistulae (accessed 26 March 2020).
- Friedenstein, A., Chailakhyan, R., Latsinik, N., Panasyuk, A., Keiliss-Borok, I. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation, 17, 331–340.10.1097/00007890-197404000-000014150881
- García-Olmo, D., García-Arranz, M., Herreros, D., Pascual, I., Peiro, C., Rodríguez-Montes, J. A. (2005). A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum,48 (7), 1416–1423.10.1007/s10350-005-0052-615933795
- Garcia-Olmo, D., Herreros, D., Pascual, I., Pascual, J. A., Del-Valle, E., Zorilla, J., De La-Quintana, P., Garcia-Arranz, M., Pascual, M. (2009). Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase ii clinical trial. Dis. Colon Rectum,52 (1),79–86.10.1007/DCR.0b013e318197348719273960
- Gonzalez-Rey, E., Anderson, P., González, M. A., Rico, L., Büscher, D., Delgado, M. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58 (7), 929–939.10.1136/gut.2008.168534
- Hellers, G., Bergstrand, O., Ewerth, S., Holmstrom, B. (1980). Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut, 21 (6), 525–527.10.1136/gut.21.6.525
- Khalif, I. (2013). Clinical Guidelines for the Diagnosis and Treatment of Adult Patients with Chronic Paraproctitis (fistulas of the anus, fistula of the rectum). Association of Coloproctology Russia, Moscow. 20 pp.
- Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Ruchkina, I. N., Konoplyannikov, A. G. (2013). Cell therapy for refractory Crohn’s disease. Cell Technol. Biol. Med., 3, 145–152.10.1007/s10517-013-2297-8
- Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Konoplyannikov, A. G., Ruchkina, I. N., Lishchinskaya, A. A. (2014). Combined biological therapy of the fistula form of Crohn’s disease. Clinical demonstration. Ther. Arch., 86 (2), 102–105.
- Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., Dazzi, F. (2003). Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood, 101, 3722–3729.10.1182/blood-2002-07-2104
- Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringden, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol., 31, 890–896.10.1016/S0301-472X(03)00110-3
- Lei Yea, Xiaowei Wua, Na Yua, Jingxin Panb, Lianming Liaoc, Fangyu (2016). Clinical efficacy and safety of stem cells in refractory Crohn’s disease: A systematic review. Wang J. Cell. Immunother., 2 (1), 21–27.10.1016/j.jocit.2016.01.001
- Lichtenstein, G. R., Van, S., Bala, M., Blank, M., Sands, B. E. (2005). Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology, 128, 862–869.10.1053/j.gastro.2005.01.04815825070
- Munkholm, P., Langholz, E., Davidsen, M., Binder, V. (1995). Disease activity courses in a regional cohort of Crohn’s. Scand. J. Gastroenterol., 30, 699–706.10.3109/003655295090963167481535
- Panes, J. (2016). Stem cell therapy for perianal fistulas in Crohn’s disease. Gastroenterol. Hepatol., 12 (10), 637–640.
- Rutgeerts, P., Feagan, B. C., Lichtenstein, G. R., Mayer, LK. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., Hanauer, S. B. (2004). Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology, 126, 402–413.10.1053/j.gastro.2003.11.01414762776
- Sachar, D. B., Andrew, H. A., Farmer, R. G., Pallone, F. (1992). Proposed classification of patient subgroups in Crohn’s disease. Gastroenterol. Intern., 5, 141–154.
- Sandborn, W. J., Fazio, V. W., Feagan, B. C., Hanauer, S. B. (2003). AGA technical review on perianal Crohn’s disease. Gastroenterology, 125, 1508–1530.10.1016/j.gastro.2003.08.02514598268
- Schnitzler, E., Fielder, H., Ferrante, M., Noman, M., Arijs, I., Assche, G. V., Hoffman, I., Van Steen, K., Vermeire, S., Rutgeerts, P. (2009). Mucosal healing predicts long-term outcome for maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis., 15, 1295–1301.10.1002/ibd.2092719340881
- Schwartz, D. A., Loftus, E. V., Jr., Tremaine, W. J., Panaccione, R., Harmsen, W. S., Zinsmeister, A. R., Sandborn, W. J. (2002). The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology, 122 (4), 875–880.10.1053/gast.2002.3236211910338
- Sensebe, L., Krampera, M., Schrezenmeier, H., Bourin, P., Giordano, R. (2010). Mesenchymal stem cells for clinical application. Vox Sang, 98, 93–107.10.1111/j.1423-0410.2009.01227.x19663934
- Solberg, I. C., Yarn, M. H., Hoie, O., Stray, N., Sauar, J., Jahsen, J., Moum, B., Lygren, I. (2007). Clinical course in Crohn’s disease: Results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol., 5, 1430–1438.10.1016/j.cgh.2007.09.00218054751
- Solberg, I. C., Lygren, I., Jahnsen, J., Vatn, M. H. (2008). Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut, 57, A15.
- Stappenbeck, T., Miyoshi, H. (2009). The role of stromal stem cells in tissue regeneration and wound repair. Science, 324, 1666–1669.10.1126/science.117268719556498
- Tang, L. Y., Rawsthorne, P., Bernstein, C. N. (2006). Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin. Gastroenterol. Hepatol., 4 (9), 1130–1134.10.1016/j.cgh.2006.06.02116905369
- Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I., Pavlov, V. V. (2004). The preparation and use in medicine, cell cultures of mesenchymal stem cells of bone marrow. Bull. Russ. Acad. Med. Sci., 59 (9), 71–76.
- Williamson, P. R., Hollinger, M. D., Larch, S. W., Ferrara, A. (1995). Twenty-year review of the surgical management of perianal Crohn’s disease. Dis. Colon. Rectum, 38, 389–392.10.1007/BF020542277720446
- Zuk, P., Zhu, M., Ashjian, P., De Ugarte, D., Huang, J., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., Hedrick, M. H. (2002). Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell, 13, 4279–4295.10.1091/mbc.e02-02-010513863312475952